Skip to main content
logo
Mahamaya Lifesciences Limited (BOM:544611)
India flag India · Delayed Price · Currency is INR
165.65
-6.35 (-3.69%)
At close: Jul 23, 2026

Mahamaya Lifesciences Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
3,2893,2892,6421,6161,371899.19
Revenue Growth
17.01%24.46%63.54%17.83%52.50%-
Gross Profit
540.34540.34374.97224.48186.77146.24
Operating Income
312.75312.75229.51119.9684.3154.62
Net Income
165.23165.23128.1253.7637.5127.23
Earnings Per Share
8.338.337.553.912.731.98
EPS Growth
6.17%10.40%92.78%43.36%37.88%-

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
393.99393.9939.1630.1430.4413.65
Total Debt
907.37907.37580.35546.26243.73191.65
Net Cash (Debt)
-513.38-513.38-541.19-516.11-213.28-178
Net Cash Growth
------
Net Cash Per Share
-25.88-25.88-31.87-37.57-15.53-12.96

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-295.24-295.24-33.05-234.611.2421.62
Capital Expenditures
-88.08-88.08-50.44-15.13-28.94-32.69
Free Cash Flow
-383.32-383.32-83.49-249.73-17.7-11.07
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
16.43%16.43%14.19%13.89%13.62%16.26%
Operating Margin
9.51%9.51%8.69%7.42%6.15%6.08%
Pretax Margin
7.26%7.26%6.53%4.60%3.72%4.14%
Profit Margin
5.02%5.02%4.85%3.33%2.73%3.03%
FCF Margin
-11.66%-11.66%-3.16%-15.46%-1.29%-1.23%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
19.9321.32----
PS Ratio
1.181.07----